Press release
Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Avidity Biosciences
"Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Facioscapulohumeral Muscular Dystrophy Therapeutics Market.
The report provides a detailed description of the Facioscapulohumeral Muscular Dystrophy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Facioscapulohumeral Muscular Dystrophy Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Facioscapulohumeral Muscular Dystrophy therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Facioscapulohumeral Muscular Dystrophy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Facioscapulohumeral Muscular Dystrophy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Facioscapulohumeral Muscular Dystrophy treatment market.
Learn More about the Clinical and Commercial Development Activities in the Facioscapulohumeral Muscular Dystrophy Therapeutics Domain:
https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Facioscapulohumeral Muscular Dystrophy Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Facioscapulohumeral Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Facioscapulohumeral Muscular Dystrophy Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Facioscapulohumeral Muscular Dystrophy (FSHD) Therapeutics Analysis
There are currently no disease-modifying treatments for FSHD; supportive care is the mainstay of managing FSHD. This care primarily occurs in the context of physical therapy and rehabilitation exercises. Managing pain and fatigue in FSHD patients is essential, as both symptoms can affect patient psychology. Chronic pain is manageable with analgesic and antidepressant therapy to improve the quality of life in FSHD patients
Several major pharma and biotech companies are developing therapies for Facioscapulohumeral Muscular Dystrophy. Several of the therapies are in the advanced stages of clinical development and are expected to hit the market in the near future.
Facioscapulohumeral Muscular Dystrophy (FSHD) Companies in the Therapeutics Market Include:
• Fulcrum Therapeutics
• Dyne Therapeutics.
• Hoffmann-La Roche
• aTyr Pharma, Inc.
• Avidity Biosciences, Inc.
And Many Others
Emerging and Marketed Facioscapulohumeral Muscular Dystrophy (FSHD) Therapies Covered in the Report Include:
• Losmapimod: Fulcrum Therapeutics
• DYNE-301: Dyne Therapeutics
• AOC 1020: Avidity Biosciences
• MC-DX4: miRecule
• Losmapimod: Fulcrum Therapeutics
And Many More
Get an in-depth Assessment of the Emerging Therapies and Facioscapulohumeral Muscular Dystrophy Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Current Treatment Patterns
4. Facioscapulohumeral Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Facioscapulohumeral Muscular Dystrophy Late-Stage Products (Phase-III)
7. Facioscapulohumeral Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Facioscapulohumeral Muscular Dystrophy Discontinued Products
13. Facioscapulohumeral Muscular Dystrophy Product Profiles
14. Facioscapulohumeral Muscular Dystrophy Companies
15. Facioscapulohumeral Muscular Dystrophy Drugs
16. Dormant and Discontinued Products
17. Facioscapulohumeral Muscular Dystrophy Unmet Needs
18. Facioscapulohumeral Muscular Dystrophy Future Perspectives
19. Facioscapulohumeral Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Atopic Dermatitis Market
https://www.delveinsight.com/report-store/atopic-dermatitis-market
Concussions Market
https://www.delveinsight.com/report-store/concussions-market
Human Immunodeficiency Virus Type-1 (HIV-1) Market
https://www.delveinsight.com/report-store/human-immunodeficiency-virus-type-1-hiv-1-market
Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market
Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market
Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market
Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market
Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market
Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market
Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market
Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Avidity Biosciences here
News-ID: 3129533 • Views: …
More Releases from DelveInsight Business Research LLP
Alopecia Areata Market Size in the 7MM is going to be ~USD 552 million in 2025, …
DelveInsight's "Alopecia Areata Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of desmoid tumor, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock key insights into the Alopecia Areata Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Alopecia Areata…
Chronic Inflammatory Demyelinating Polyneuropathy Market Size (US) was ~USD 1,38 …
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of desmoid tumor, historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock key insights into the Chronic Inflammatory Demyelinating Polyneuropathy Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis,…
Graves' disease Market Size (7MM) was ~USD 4,400 Million in 2023 and is expected …
DelveInsight's "Graves' Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Graves' Disease, historical and forecasted epidemiology as well as the Graves' Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Explore Graves' Disease Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Graves' Disease Market Report
• In December…
Pemphigus Vulgaris Treatment Market Size in the 7MM is projected to grow at a si …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore In-depth insights into the evolving Pemphigus Vulgaris Market. Download sample report @ https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Pemphigus Vulgaris Market Report
• In December 2025, Cabaletta Bio initiated a phase…
More Releases for Facioscapulohumeral
Facioscapulohumeral Muscular Dystrophy Clinical Trial Pipeline Shows Potential w …
DelveInsight's "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
Facioscapulohumeral Muscular Dystrophy (FSHD) Market is projected to reach USD 4 …
The global Facioscapulohumeral Muscular Dystrophy (FSHD) Market was valued at USD 210 million in 2024 and is projected to reach USD 482 million by 2034, expanding at a CAGR of 8.6% during the forecast period (2025-2034). The market is driven by rising diagnosis rates, advancements in genetic testing, improved clinical awareness among neuromuscular specialists, and accelerating drug development targeting the underlying molecular mechanisms of FSHD.
Download Full PDF Sample Copy of…
Facioscapulohumeral Muscular Dystrophy (FSHD) Market Massive Growth opportunity …
Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic muscle disorder characterized by progressive weakness of facial, shoulder, and upper arm muscles, and eventually lower body muscles. It is the third most common type of muscular dystrophy, affecting approximately 1 in 8,000 to 1 in 20,000 individuals worldwide.
FSHD is typically caused by abnormal expression of the DUX4 gene due to genetic mutations on chromosome 4. While there is currently no approved…
Facioscapulohumeral Muscular Dystrophy Market Expected to Evolve Through 2034 Am …
Facioscapulohumeral Muscular Dystrophy (FSHD) is one of the most prevalent forms of muscular dystrophy, characterized by progressive skeletal muscle weakness that initially affects the face, shoulders, and upper arms. The condition is genetically linked to abnormal expression of the DUX4 gene, most commonly caused by contraction of the D4Z4 repeat on chromosome 4. FSHD can significantly impact mobility, quality of life, and daily function, though disease progression varies widely among…
Facioscapulohumeral Muscular Dystrophy Clinical Trials, Treatment Drugs, Pipelin …
DelveInsight's, "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this…
Facioscapulohumeral Muscular Dystrophy Pipeline 2024 | Fulcrum Therapeutics, Dyn …
DelveInsight's, "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this…
